ProCE Banner Activity

Shifting the Paradigm: Prioritizing Obesity Management in Cardiometabolic Disease

Clinical Thought

GLP-1 receptor agonists and SGLT2 inhibitors have benefits such as weight loss and reduction of cardiovascular risk, in addition to lowering A1C. In this commentary, an expert provides his thoughts on prioritizing weight management in patients with cardiometabolic diseases.

Released: February 07, 2023

Expiration: February 06, 2024

Share

Faculty

Michael Jensen

Michael Jensen, MD

Tomas J. Watson, Jr. Professor in Honor
of Dr. Robert L. Frye
Endocrine Research Unit
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Novo Nordisk

Faculty Disclosure

Primary Author

Michael Jensen, MD

Tomas J. Watson, Jr. Professor in Honor
of Dr. Robert L. Frye
Endocrine Research Unit
Mayo Clinic
Rochester, Minnesota

Michael D. Jensen, MD: researcher: Novo Nordisk.